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Abstract
Objective: Alterations: p53 genes are turning out to be the most common genetic alterations in human
cancers. Due to long half-life of mutated p53, its detection is possible by immunohistochemistry.
Proliferating cejl nuclear antigen (PCNA) is expressed by dividing cells, hence has been shown to
correlate with prognosis. We have used monoclonal antibodies protein DO-7 (p53) and PC1O (PCNA)
to see whether their expression correlates with histological grading in meningethelial tumour.
Material and Methods: Twenty nine meningiomas (20 benign, 7 atypical and 2 malignant) were
selected from the records of our laboratory. p53 and PCNA expression was sought by
immunohistochemistry using Peroxidase Anti Peroxidase (PAP) technique.
Results: Four benign and 2 atypical meningiomas showed weak staining for p53. Both malignant
meningiomas showed strong positivity for p53. Six benign meningiomas had less than 5% PCNA
positivity, one 10% positivity and three showed 20% positivity. PCNA positivity ranged for 10-80% in
atypical meningiomas. In two malignant meningiomas PCNA positivity was 70% and 90%.
Conclusion: It is worthwhile to include p53 and PCNA expression alongwith histologic assessment in
predicting outcome of meningiomas. A larger series with complete follow-up is essential in assessing
value of these markers which unfortunately remains a dream in our country (JPMA 49:241, 1999).
Introduction
Alterations in p53 gene are turning out to be the most common genetic alterations in human cancer1.
Increasing evidence attributes p53 dys-regulation a crucial role in the development of cancer and its
prognosis 2. The expression of mutated p53 has been documented in several epithelial and nonepithelial malignancies, including nervous system. This loss of tumor suppresser activity has also been
seen in atypical and meningiomas 3-6.
PCNA is expressed in dividing cells and appears in the nucleas in late Gl phase. It peaks in S phase and
subsides in G2 and M phases. Thus its level of expression correlates with cellular proliferative activity
and DNA synthesis5.
Assessment of prognosis in meningiomas is not easy by routine histo-pathological examination. We
aimed at identifying criteria based on tumor markers, in the meningothelial tumors, which would help
to predict the aggressive behaviour of some of these neoplasms. We carried out a prospective study at
The Aga Khan University Medical Centre, Karachi to correlate the histological criteria for predicting
aggressive behaviour of the tumor with expression of p53 and PCNA in benign, atypical and frankly
malignant tumors.
Materials and Methods
A total of 29 meningiornas were reported in the period ranging from June 1993 to June 1996, by the
Histopathology Department of The Aga Khan University Medical Centre, Karachi. Out of these 20 had
been reported as benign, 7 as atypical and 2 as malignant tumors. Out of the 20 benign tumors we

randomly selected every second case for the study whereas all the atypical and malignant meningiomas
were included in the study.
The material received for examination was routinely processed, cut at 5m thickness and stained with
the standard Haematoxylin and Eosin stain. Tumors were categorised in three groups, i.e. benign,
atypical and malignant according to the scores which they secured by using the criteria of
hypercellularity, nuclear pleomorphism, mitosis, necrosis, loss of architecture and evidence of brain
invasion6. The tumors with scores of 0-4 were called benign, whereas tumors scoring more than 11 as
malignant ones (Table).

The tumors having a score of 5-11 were classified as atypical meningiomas.
The detection of p53 and PCNA was done on formalin fixed, paraffin embedded tissue sections by
immunohistochemistry using PAP technique. The antigen retrieval was done by subjecting the sections
to microwave heating. Primary antibodies against monoclonal mouse anti human p53 protein DO-7 and

monoclonal mouse anti-proliferating cell nuclear antigen (PCNA) PC10 (both by DAKO) were used
followed by incubation with rabbit anti-mouse immunoglobulin, followed by final incubation with
polyclonal mouse PAP tomplex. The colour development was done by Di-aminobenzidine. The brown
nuclear staining was taken as positive for both the markers. Positivity for PCNA was calculated as
number of nuclei/100 cells taking a brown stain whereas for p53, the blue nuclei were taken as
negative, mild, brown staining was taken as +, moderate brown colour was ++ and a dark brown colour
was considered as +++ (strongly positive). The scoring was done by 2 pathologists independently
followed by a combined review of the material.
P53 and PCNA expression in different category of tumors is shown in table. Out of 10 benign
meningiomas, 6 were completely negative for p53 and 4 showed very weak nuclear staining. Regarding
PCNA, 7 benign tumors showed staining in less than 5% of the nuclei and 3 showed positivity in 10%
of the nuclei. In the group of atypical meningiomas, 5 did not show positivity for p53 and 2 showed
weak staining. The PCNA positivity in this group ranged from 5-40%. Only 2 malignant tumors were
available and showed strong positivity for p53 with high proliferative activity as detected by PCNA
ranging from 35% and 45% nuclei.
Tumor suppressor gene p53 is considered to be the policeman of the genome. When mutated it allows
non lethal genetic defects to persist ultimately leading to neoplasia. p53 gene is frequently mutated in
wide variety of human tumors. Structural rearrangements, deletions and point mutations, result in loss
of normal p53 function. The tumor suppresser gene (p53) encodes 53 LD, nuclear phospho-protein,
involved in cell cycle control, particularly, in transit from G0/G I to the S phase2. There have been few
studies in which p53 mutation has been sought in meningiomas and those studies have been in context
of progressively increased accumulation in benign, atypical and malignant meningiomas3-6. In this
study, we studied mutated p53 protein expression in 19 meningiomas by doing immunohistochemistry.
An attempt was made to
correlate p53 expression with number of cells in cycle as detected by the proliferation marker PCNA
and correlating both the result with histological grading obtained on H & E staining. It appears that the
expression of p53 be an uncommon event in benign and atypical meningiomas and only occurs when
the malignant transformation has occurred. PCNA whose efficacy as a proliferation marker is well
tested7,8 showed correspondingly higher score in three categories of Meningiomas. However, there
were 4 tumors in benign category with score of 10%. The score of atypical ranged from 5-40% and 2
malignant tumors showed a score higher than 35%. Although only follow up of these patients will
confirm the potential of PCNA as a prognostic marker, it appears at this stage, that adequate
categorisation can be done by this marker and will complement the scoring system in meningeal tumors
and thus minimise the subjectivity and observer bias. The overlap category of atypical meningiomas
with a higher score and PCNA ositivity needs follow up for recurrence. We admit that the sample size
in this study is relatively small (specially the malignant meningiomas which are very rare tumors) but
we think it is worth while to co-relate the three criteria (histological grading, p53 and PCNA) to predict
the probable outcome of the histologically aggressi e menigiomas.
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